Infectious complications associated with tocilizumab following chimeric antigen receptor T-cell therapy
Journal of Oncology Pharmacy Practice · 19.05.2026
DOI: 10.1177/10781552261453510 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Oncology Pharmacy Practice, online erschienen am 19.05.2026. Verfasst von Virginia Bland und 1 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacy Department, Northwestern Memorial Hospital, Chicago, Illinois, USA. Die Arbeit nennt 16 Literaturangaben.
Abstract (Originalsprache)
Purpose
Chimeric antigen receptor (CAR) T-cell therapy has reshaped the outlook for patients with relapsed or refractory hematologic malignancies. In pivotal trials, infections occurred in 19–56% and 42–69% of patients receiving CD19- and B-cell maturation antigen (BCMA)-directed therapies, respectively. Administration of corticosteroids and tocilizumab may further increase the risk of infection. The study purpose is to determine if tocilizumab administration leads to a higher incidence of infection after receiving CAR T-cell therapy.
Methods
This is a single-center retrospective study analyzing 198 patients who received CAR T-cell treatment from June 1, 2018 through August 21, 2023. Patients who received tocilizumab after CAR T-cell administration were compared to patients who did not. The primary outcome is the incidence of documented infection within 90 days of receiving CAR T-cell therapy.
Results
During their index admission, 100 patients received tocilizumab after CAR T-cell therapy and 98 patients did not receive tocilizumab. Within 90 days of CAR T-cell administration, the incidence of any infection was 31.6% in patients who did not receive tocilizumab compared to 33% in patients who received tocilizumab (p = 0.837). Positive bacterial cultures occurred in 9.2% of patients who did not receive tocilizumab compared to 20% of patients who did receive tocilizumab (p = 0.031); however, this was not supported with logistic regression (p = 0.076).
Conclusion
In conclusion, tocilizumab administration did not appear to increase the risk of infection within 90 days after CAR T-cell therapy. These results are limited by the retrospective, single-center nature of the study. A multicenter cohort is recommended to further validate these results.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Pharmacy Department, Northwestern Memorial Hospital, Chicago, Illinois, USA.
ORCID-Profile: Virginia Bland, Daniel Przybylski
Zitieren
APA
Bland, V., & Przybylski, D. (2026). Infectious complications associated with tocilizumab following chimeric antigen receptor T-cell therapy. Journal of Oncology Pharmacy Practice. https://doi.org/10.1177/10781552261453510
Vancouver
Bland V, Przybylski D. Infectious complications associated with tocilizumab following chimeric antigen receptor T-cell therapy. Journal of Oncology Pharmacy Practice. 2026. doi:10.1177/10781552261453510
BibTeX
@article{Bland2026,
author = {Bland, Virginia and Przybylski, Daniel},
title = {Infectious complications associated with tocilizumab following chimeric antigen receptor T-cell therapy},
journal = {Journal of Oncology Pharmacy Practice},
year = {2026},
doi = {10.1177/10781552261453510}
}
EUVIMED